Lumida
/ATRC
⌘K
AtriCure Inc

AtriCure Inc

ATRC
$54.54USD+2.98%+1.58 today

MARKET CAP

2.8B

P/E (TTM)

FWD P/E

DAY RANGE

$54 – $55

52W RANGE

$25
$56

AI Summary

Stalk
StalkMedium

ATRC has broken to a new 52-week high in a strong uptrend, confirmed by volume and momentum, but overbought conditions and stretched valuations warrant patience for a pullback into the rising EMA zone before engaging.

  • 2025 revenue $534M (+15% YoY) driven by AtriClip Flex Mini, CryoSphere Max
  • Pain management sales up 28% in 2025 on CryoSphere Max adoption
  • Negative earnings yield and weak profitability metrics signal return challenges
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$274.3M$330.4M$399.2M$465.3M$534.5M
YoY %+32.8%+20.4%+20.8%+16.5%+14.9%
P / Sales11.7x6.2x4.1x3.1x3.5x
EV / Sales12.0x6.4x4.3x3.1x3.5x
Gross Profit, Adj.$205.9M$245.9M$300.4M$347.5M$400.8M
YoY %+37.9%+19.5%+22.1%+15.7%+15.3%
Margin %75.0%74.4%75.2%74.7%75.0%
EV / Gross Profit16.0x8.6x5.7x4.2x4.7x
EBITDA, Adj.$-36.9M$-31.0M$-11.9M$-21.3M$11.1M
YoY %-5.2%+16.0%+61.7%-79.3%+152.1%
Margin %-13.4%-9.4%-3.0%-4.6%2.1%
EV / EBITDA-89.2x-68.5x-143.1x-68.7x170.0x
EBIT$55.2M$-42.7M$-26.7M$-40.0M$-9.4M
YoY %+224.8%-177.3%+37.5%-50.0%+76.4%
Margin %20.1%-12.9%-6.7%-8.6%-1.8%
EV / EBIT59.6x-49.7x-63.7x-36.5x-199.4x
Net Income$50.2M$-46.5M$-30.4M$-44.7M$-11.4M
YoY %+204.2%-192.6%+34.5%-46.8%+74.4%
Net Margin18.3%-14.1%-7.6%-9.6%-2.1%
EPS (GAAP)$1.09-$1.02-$0.66-$0.95-$0.24
YoY %+195.6%-193.6%+35.3%-43.9%+74.7%